…
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Therma Bright Inc (THRM.V) is a small-cap issuer listed on the TSX Venture Exchange; limited public information is available about its core business, assets and strategic plan. Because operational details and disclosed growth drivers are unclear, investors should view the company as a speculative exposure that may benefit from future operational developments or clearer disclosure.
Material risks include scant public disclosure, low market liquidity, likely need for additional financing, execution risk typical of early-stage issuers and potential regulatory or operational uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Income before tax | -4.34M | -2.45M | -3.77M | -5.88M | -8.61M |
| Net income | -4.34M | -2.45M | -3.77M | -5.88M | -8.61M |
| Selling general administrative | 1.73M | 1.15M | 3.18M | 4.94M | 7.17M |
| Gross profit | 0.05M | 0.03M | -0.05M | 0.06M | 0.00M |
| Reconciled depreciation | 0.09M | 0.10M | 0.08M | 0.15M | 0.06M |
| Ebit | - | - | -3.68M | -5.84M | -8.59M |
| Ebitda | - | - | -3.60M | -5.68M | -8.54M |
| Depreciation and amortization | - | - | 0.08M | 0.15M | 0.06M |
| Operating income | -1.77M | -1.23M | -3.60M | -5.68M | -8.54M |
| Other operating expenses | - | - | 3.70M | 5.98M | 8.60M |
| Interest expense | 0.00M | 0.01M | 0.01M | 0.00M | 0.00M |
| Net interest income | -0.00M | -0.01M | -0.01M | -0.00M | 0.00M |
| Income tax expense | - | - | 0.01M | 0.00M | - |
| Total revenue | 0.08M | 0.03M | 0.02M | 0.14M | 0.00M |
| Total operating expenses | 1.85M | 1.26M | 3.70M | 5.90M | 8.60M |
| Cost of revenue | 0.03M | 0.00M | 0.08M | 0.08M | 0.00M |
| Total other income expense net | -2.57M | -1.21M | -0.08M | -0.04M | -0.02M |
| Net income from continuing ops | -4.34M | -2.45M | -3.77M | -5.88M | -8.61M |
| Net income applicable to common shares | - | - | - | -5.88M | -8.61M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Total assets | 0.25M | 3.19M | 2.21M | 4.00M | 2.24M |
| Intangible assets | 0.03M | 0.52M | 0.62M | 0.11M | - |
| Total liab | 1.81M | 1.87M | 2.16M | 1.25M | 0.93M |
| Total stockholder equity | -1.57M | 1.32M | 0.04M | 2.75M | 1.32M |
| Common stock | - | - | - | 20.86M | 18.91M |
| Capital stock | 26.55M | 25.27M | 21.83M | 20.86M | 18.91M |
| Retained earnings | -42.57M | -38.23M | -35.78M | -32.01M | -26.13M |
| Other assets | - | - | - | 0.20M | - |
| Cash | 0.00M | 0.00M | 0.18M | 3.08M | 1.78M |
| Total current liabilities | 1.81M | 1.87M | 2.14M | 1.16M | 0.89M |
| Net debt | 0.04M | 0.04M | - | - | - |
| Short long term debt | 0.04M | 0.04M | 0.04M | - | - |
| Other stockholder equity | - | - | - | 13.90M | 8.53M |
| Property plant equipment | - | - | - | 0.11M | 0.08M |
| Total current assets | 0.20M | 0.39M | 0.45M | 3.58M | 1.95M |
| Long term investments | 0.00M | 2.12M | 0.84M | - | - |
| Net tangible assets | - | - | - | 2.64M | 1.11M |
| Short term investments | 0.04M | - | - | - | - |
| Net receivables | - | - | 0.00M | 0.25M | 0.10M |
| Long term debt | - | - | - | 0.04M | 0.04M |
| Inventory | 0.13M | 0.17M | 0.17M | 0.17M | 0.05M |
| Accounts payable | 0.99M | 1.07M | 1.43M | 0.34M | 0.49M |
| Non currrent assets other | - | 2.80M | - | - | - |
| Non current assets total | 0.05M | 2.80M | 1.76M | 0.42M | 0.29M |
| Capital lease obligations | 0.00M | 0.03M | 0.05M | 0.07M | 0.00M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Investments | 0.00M | -0.14M | -0.69M | -0.20M | -0.30M |
| Change to liabilities | - | - | - | 0.68M | 1.27M |
| Total cashflows from investing activities | - | - | - | -0.20M | -0.30M |
| Net borrowings | -0.03M | -0.03M | - | -0.01M | -0.06M |
| Total cash from financing activities | 0.15M | 0.97M | -0.03M | 5.31M | 3.87M |
| Change to operating activities | - | - | - | -0.09M | -0.11M |
| Net income | -4.34M | -2.45M | -3.77M | -5.88M | -8.61M |
| Change in cash | 0.00M | -0.18M | -2.90M | 1.30M | 0.72M |
| Begin period cash flow | 0.00M | 0.18M | 3.08M | 1.78M | 1.06M |
| End period cash flow | 0.00M | 0.00M | 0.18M | 3.08M | 1.78M |
| Total cash from operating activities | -0.15M | -1.01M | -2.17M | -3.80M | -2.86M |
| Issuance of capital stock | 0.17M | 1.00M | 0.00M | 5.31M | 3.93M |
| Depreciation | 0.09M | 0.10M | 0.08M | 0.15M | 0.06M |
| Other cashflows from investing activities | - | - | - | -0.20M | -0.20M |
| Change to inventory | 0.04M | 0.00M | -0.93M | -0.12M | -0.03M |
| Change to account receivables | - | 0.00M | 0.12M | -0.12M | -0.10M |
| Other cashflows from financing activities | - | - | -0.69M | -0.69M | -0.06M |
| Change to netincome | - | - | - | 1.58M | 4.57M |
| Capital expenditures | 0.00M | 0.00M | 0.27M | 0.00M | 0.30M |
| Change in working capital | 1.31M | -0.21M | 1.17M | 0.35M | 1.12M |
| Stock based compensation | 0.17M | 0.30M | 0.30M | 1.57M | 4.57M |
| Other non cash items | 0.05M | 0.05M | -0.01M | 0.00M | 3.55M |
| Free cash flow | -0.15M | -1.01M | -2.44M | -3.80M | -3.16M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| THRM Therma Bright Inc |
0.01 20.00% |
0.03 | - | - | 49.94 | 2.54 | 50.00 | -5.84 |
| TLT Theralase Technologies Inc. |
0.01 2.70% |
0.19 | - | - | 90.07 | 82.51 | 90.31 | -12.06 |
| CNVI Conavi Medical Corp. |
-0.01 4.55% |
0.10 | - | - | 66.65 | - | 95.30 | - |
| PINK Perimeter Medical Imaging AI Inc |
-0.02 11.11% |
0.16 | 4.13 | - | 18.78 | 11.34 | 20.22 | -2.55 |
| CHER Cheelcare Inc. |
-0.03 2.40% |
1.22 | - | - | 20.92 | 106.42 | 21.26 | - |
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Roberto Fia C.F.A. | Chairman, Pres & CEO | 1970 |
| Mr. Victor Hugo C.M.A., CPA | Chief Financial Officer | 1970 |
| Mr. Michael Mayo | Director of Sales | NA |
| Mr. Roberto Fia C.F.A. | Chairman, President & CEO | 1970 |
| Mr. Sung Min Myung C.A., CPA | Chief Financial Officer | 1986 |
| Mr. Sung Min Myung C.A., CPA | Chief Financial Officer | 1987 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.